» Articles » PMID: 24535736

Protective Efficacy of Babesia Gibsoni Culture-derived Exoantigens Against the Challenge Infection in Dogs

Overview
Journal Parasitol Res
Specialty Parasitology
Date 2014 Feb 19
PMID 24535736
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study is to determine the efficacy of exoantigens derived from Babesia gibsoni cultures to induce protective immunity against challenge exposure of virulent organisms. An attenuated B. gibsoni Oita strain was maintained in vitro by the microaerophilus stationary phase (MASP) method, and exoantigens-containing supernatant fluids were collected for preparation of the immunization. Two dogs received three subcutaneous immunizations with a 20-day interval of B. gibsoni exoantigens plus 0.5 mg saponin (Quil A). On day 68 after the prime immunization, the immunized dogs and control dogs were challenged intravenously with 2 × 10(8) virulent parasites of a homologous B. gibsoni strain. The results showed that exoantigens could induce a high degree of protection against virulent homologous challenge exposure. Two dogs immunized with exoantigens showed a lower parasitemia, accompanied by a slight decrease in the PCV that returned to normal values. Control dogs developed typical acute clinical signs, including severe anemia and hyperthermia. The immunization elicited humoral immune responses. In dogs immunized with exoantigens, the maximum antibody titer was 2,560 and 5,120 by indirect fluorescent antibody test (IFAT), respectively. Preliminary Western blot analysis of the immunogen revealed five dominant proteins of molecular weights of 18, 37, 43, 50, and 57 kDa. These results suggested that the culture-derived exoantigens were candidates for non-viable vaccine.

References
1.
Boozer A, Macintire D . Canine babesiosis. Vet Clin North Am Small Anim Pract. 2003; 33(4):885-904, viii. DOI: 10.1016/s0195-5616(03)00039-1. View

2.
Jefferies R, Ryan U, Jardine J, Robertson I, Irwin P . Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy. Exp Parasitol. 2007; 117(2):115-23. DOI: 10.1016/j.exppara.2007.03.016. View

3.
Fukumoto S, Xuan X, Nishikawa Y, Inoue N, Igarashi I, Nagasawa H . Identification and expression of a 50-kilodalton surface antigen of Babesia gibsoni and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay. J Clin Microbiol. 2001; 39(7):2603-9. PMC: 88193. DOI: 10.1128/JCM.39.7.2603-2609.2001. View

4.
Schetters T . Vaccination against canine babesiosis. Trends Parasitol. 2005; 21(4):179-84. DOI: 10.1016/j.pt.2005.02.006. View

5.
Schetters T, Scholtes N, Kleuskens J, Bos H . Not peripheral parasitaemia but the level of soluble parasite antigen in plasma correlates with vaccine efficacy against Babesia canis. Parasite Immunol. 1996; 18(1):1-6. DOI: 10.1046/j.1365-3024.1996.d01-1.x. View